Gilead Sciences Inc.’s hepatitis C cure set off a firestorm of criticism over high drug prices in 2014 that hasn’t let up since. Now an executive says the company can’t cut the product’s price because middlemen who manage drug benefits would refuse to cover it.
Category: Merck
Biotech Stock Mailbag: OncoSec Medical and the Quest to Turn Cold Tumors Hot
This week, I will take a closer look at a new approach in cancer immunotherapy from a tiny biotech company — OncoSec Medical . Before I get started, a word or two of caution: OncoSec is a micro-cap biotech company with a single-digit stock price and an enterprise value of just $2.7 million.
‘Wait until you can’t take it, and buy. Then wait until you are euphoric, and sell.’
There’s a reason why this market’s so hard to kill — the rotations are endless and they are positive! Two weeks ago, you couldn’t give away the drug stocks. Now they are all things of beauty.
Merck Takes $1.9 Billion Charge on Hepatitis C Drug
Merck & Co. will take an impairment charge of $1.9 billion, after taxes, related to the development of a hepatitis C treatment, the company said in a filing Thursday.
Merck Stops Clinical Trial of Alzheimer’s Drug
This Thursday, Dec. 18, 2014, file photo shows the Merck logo on a stained glass panel at a Merck company building in Kenilworth, N.J. Merck & Co. reports financial results Thursday, Feb. 2, 2017.
Merck Alzheimer’s Drug Study Halted Early for Futility
Another Alzheimer’s disease drug has failed to help patients. This time, it’s verubecestat, a BACE inhibitor from Merck .
Merck Matches Profit Expectations But Sales Come Up a Bit Short
Merck & Co. Inc. reported Thursday fourth-quarter earnings that rose to $1.18 billion, or 42 cents a share, from $976 million, or 35 cents a share, in the same period a year ago.
Bristol-Myers Falls Further Behind Merck in Lung Cancer Race
Bristol-Myers Squibb Co. fell after the drugmaker said it wouldn’t seek accelerated approval for a combination of its drugs to treat first-line lung cancer.
Cheating Death Can Cost $200,000 as Cancer Tops Pharma Sales
Years before becoming a top cancer specialist, Eric Winer used to save money on his own medical care by talking U.S. pharmacists into giving him expired treatments for free. Winer, who has a bleeding disorder known as hemophilia, knew the drugs would still work for a brief time after the official use-by date.
Merck’s Ebola Vaccine Found to Protect Against Deadly Virus
An experimental Ebola vaccine manufactured by Merck & Co. was found to be highly protective against the deadly virus, showing promise in the fight against future outbreaks after an earlier epidemic killed thousands and highlighted a shortage of weapons to battle the disease.